IXCHIQ

關於IXCHIQ

IXCHIQ is the world’s first and only licensed chikungunya vaccine available to address this significant unmet medical need. The vaccine is currently approved in the U.S.[1], Europe[2], and Canada[3] for the prevention of disease caused by the chikungunya virus in individuals 18 years of age and older. The U.S. launch is underway while first sales in Canada and Europe are anticipated in the fourth quarter of 2024.

排程

Single dose.

副作用

Well tolerated; occasional headache, myalgia, fatigue, and fever.

我們會監控世界上的旅行中斷或威脅性事件,並通知您,這樣您就不會遇到任何意外情況

學習更多